Key result
Proteomic profiling reveals protein profiles converge across end-stage HF etiologies, favoring molecular subtyping.
Why the study?
In end-stage heart failure, it is unclear whether proteomic profiles converge across etiologies and if molecular subtyping better captures patient heterogeneity than clinical phenotyping.
Molecular subtyping via proteomics may better capture patient heterogeneity in end-stage heart failure than traditional clinical phenotyping.
Should not yet change clinical phenotyping in end-stage HF; hypothesis-generating for molecular subtyping in prospective studies.
Proteomic profiling of 149 explanted human hearts shows that, in end-stage heart failure, protein profiles converge across etiologies. Proteome profiles indicate that molecular subtyping, rather than clinical phenotyping, may better capture patient heterogeneity.
No takes yet. Share an insight, caveat, or question.
Alicia Lundby (2026) studied this question. Proteomic profiling of 149 explanted human hearts shows that protein profiles converge across etiologies in end-stage heart failure, favoring molecular subtyping over clinical phenotyping.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: